The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma. - Wikidata - wikimedia - TriplyDB

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.

http://www.wikidata.org/entity/Q37706284

about

Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis.Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.

P2860

Q37731945-CDB98046-DCC6-46B5-9FB4-CDA9E5D76EDF Q54977581-F5B0714B-20CC-4B17-9690-AAE5688A23DD Q55396331-10A7F41C-6CD6-434B-99D6-9BE12A0E95F1

P2860

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.

http://www.wikidata.org/entity/Q37706284

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The role of T790M mutation in ...... advanced lung adenocarcinoma.

@en

The role of T790M mutation in ...... advanced lung adenocarcinoma.

@nl

type

label

The role of T790M mutation in ...... advanced lung adenocarcinoma.

@en

The role of T790M mutation in ...... advanced lung adenocarcinoma.

@nl

prefLabel

The role of T790M mutation in ...... advanced lung adenocarcinoma.

@en

The role of T790M mutation in ...... advanced lung adenocarcinoma.

@nl

P1433

Q37706284-5DAD8183-8B55-45D3-8635-524B08BED2BF

P1476

Q37706284-822693B2-9AA1-4F8F-B59D-57816577FF68

P2093

Q37706284-030A7625-429F-4227-82CB-A4184DF9CD8F

Q37706284-1C12A839-D52F-45DB-81D6-0BBD56280931

Q37706284-3685E133-C9CB-46C2-95F3-0AC3A9815A12

Q37706284-6A620143-DF15-4FF9-9290-8CCF40D0EF41

Q37706284-760F46D5-8F62-4AC8-ACCE-76668724BC85

Q37706284-8F28C6D5-1CB5-4834-A1CD-44FF79D62F43

Q37706284-A9940B24-17B5-40C4-BCC8-D5D988259F5C

Q37706284-B436AF08-485D-4181-944F-383D1EB1CC9C

Q37706284-C7E9F01C-CE88-45C4-93AD-061520EF7069

Q37706284-CD25D10E-E6F8-4613-A6CA-5F6FA0CC78F4

P2860

Q37706284-04841A0B-E453-418F-841D-43CECE44BF39

Q37706284-180472B8-31D3-4AFA-8710-6D380C1EE6CD

Q37706284-1F4CA950-B3A7-4317-943E-60A5BEACBAED

Q37706284-27DA6AA4-186C-4BDB-A459-41EDE8E49EDE

Q37706284-28FDF9D9-EAAB-4D34-8D17-808DD1D4B11A

Q37706284-36C1A1F1-1857-4291-94D3-36279507E1A7

Q37706284-3AFB9BF6-ED31-4B44-B572-0FF6749860FF

Q37706284-400D5903-3574-41F3-93D1-1E6727BE3615

Q37706284-47A88925-9B6A-4EEC-8742-4FF1BC95A697

Q37706284-49D11330-1921-4FEB-A88B-977925BEC096

P304

Q37706284-537219BE-094E-446A-8BEE-A7F6067471C6

P31

Q37706284-A35E98A6-3920-48F5-AC8B-3E43C0017D58

P356

Q37706284-3517D63B-1204-49FC-9EC6-9E53373CBE94

P407

Q37706284-4D9DCBCC-F618-44D9-BB7D-D63A4E7AA9D7

P433

Q37706284-15E09FE1-32EE-442D-9E85-A62608D11FD9

P478

Q37706284-F1222729-9F53-4608-B9D6-B4327E1E3E0D

P577

Q37706284-4147F13D-D547-4723-9BC3-F36B288C8713

P698

Q37706284-7076C987-C244-49B8-A1C5-45F0F381E37E

P921

Q37706284-7331739A-6958-48E6-B74A-2D34F04ED97E

P932

Q37706284-BAB05BE4-0910-4EE0-B69C-C460FEB8C014

P356

ONCOTARGET.14007

P1433

P1476

The role of T790M mutation in ...... advanced lung adenocarcinoma.

@en

P2093

Chongrui Xu

http://www.w3.org/2001/XMLSchema#string

Ee Ke

http://www.w3.org/2001/XMLSchema#string

Feiyu Niu

http://www.w3.org/2001/XMLSchema#string

Honghong Yan

http://www.w3.org/2001/XMLSchema#string

Jian Su

http://www.w3.org/2001/XMLSchema#string

Jinji Yang

http://www.w3.org/2001/XMLSchema#string

Ning Zhao

http://www.w3.org/2001/XMLSchema#string

Qing Zhou

http://www.w3.org/2001/XMLSchema#string

Qiuyi Zhang

http://www.w3.org/2001/XMLSchema#string

Wei Deng

http://www.w3.org/2001/XMLSchema#string

P2860

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

P304

4994-5002

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.14007

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27999211

http://www.w3.org/2001/XMLSchema#string

P921

P932

5354886

http://www.w3.org/2001/XMLSchema#string